Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2018-06-18 Director's Dealing
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-06-18 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-18 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 13, 2018. It primarily details the submission of matters to a vote of securityholders at the 2018 Annual General Meeting (AGM) of uniQure N.V., including voting results on various agenda items such as adoption of annual accounts, discharge of board liability, election and re-election of directors, amendments to share plans, and reappointment of auditors. The document also references a press release about new board appointments. The content focuses on the official results of shareholder votes at the AGM, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual report, audit report, or management discussion, but specifically reports voting outcomes. Therefore, the appropriate classification is DVA with high confidence.
2018-06-15 English
S-3ASR
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus describing the securities to be offered, such as ordinary shares, warrants, rights, debt securities, purchase contracts, and units. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital raising and securities registration. It is not an announcement of a report but the actual registration statement document. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full filing, not just an announcement or certification.
2018-06-14 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock purchase plans and share incentive plans. It includes detailed information about the plans, the number of shares registered, and references to prior filings and exhibits. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. The document is lengthy (15,000 characters) and contains substantive content typical of a registration statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2018-06-14 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.